Nouvelle déclaration d'incident
No de la demande: 2022-5895
Numéro de référence du titulaire d'homologation: 2022-US-027971 and 2022-US-028081 (linked cases)
Nom du titulaire (nom légal complet, aucune abbréviation): The Hartz Mountain Corporation
Adresse: 400 Plaza Drive
Ville: Secaucus
État: New Jersey
Pays: USA
Code postal /Zip: 07094-3688
Incident chez un animal domestique
Pays: UNITED STATES
État: PENNSYLVANIA
ARLA No d'homologation ARLA No de la demande d'homologation EPA No d'homologation. 2596-139
Nom du produit: Hartz UltraGuard Plus Flea and Tick Collar (non-specific)
Autre (préciser)
CollarOui
Inconnu
Site: Animal / Usage sur un animal domestique
Inconnu
Propriétaire de l'animal
Cat / Chat
Domestic Shorthair
1
Homme
5
8
lbs
Cutanée
>1 wk <=1 mo / > 1 sem < = 1 mois
>1 wk <=1 mo / > 1 sem < = 1 mois
Système
Persisted until death
Non
Non
Mort
Treatment / Traitement
(p.ex. description des symptômes tels que la fréquence et la gravité
On 27-Jun-2022, a 5 year old, 8 pound, intact, male, Domestic Shorthair cat, in unknown condition, with no known concomitant medical conditions, was administered 1 collar of Hartz UltraGuard Plus Flea and Tick Collar (non-specific) (Tetrachlorvinphos (Rabon) / S Methoprene) via the topical route by the animal owner. On 24-Jul-2022, the cat was found deceased, still wearing the collar. No other signs preceding death were reported. A necropsy was not performed. No further information was received.
Mort
Assessment:This product contains tetrachlorvinphos, an organophosphate insecticide, that is considered to have a good margin of safety in cats. The active ingredient is poorly absorbed across intact skin. If product residue were ingested only mild GI upset would be expected. Sudden death is not expected and other causes including unknown trauma or injury, toxin exposure, and underlying disease should also be considered in this case. Without diagnostics, including necropsy, further classification of the relationship between product use and outcome cannot be made. The information contained in this report is based on self-reported statements provided to the registrant during telephone interview(s). These self-reported descriptions of an incident have not been independently verified to be factually correct or complete descriptions of the incident. For that reason, information contained in this report does not and cannot form the basis for a determination of whether the reported clinical effects are causally related to exposure to the product identified in the telephone interviews.
Propriétaire de l'animal
Cat / Chat
Domestic Shorthair
1
Homme
5
8
lbs
Cutanée
>1 wk <=1 mo / > 1 sem < = 1 mois
>1 wk <=1 mo / > 1 sem < = 1 mois
Système
Persisted until death
Non
Non
Mort
Treatment / Traitement
(p.ex. description des symptômes tels que la fréquence et la gravité
On 27-Jun-2022, a 5 year old, 8 pound, intact, male, Domestic Shorthair cat, in unknown condition, with no known concomitant medical conditions, was administered 1 collar of Hartz UltraGuard Plus Flea and Tick Collar (non-specific) (Tetrachlorvinphos (Rabon) / S Methoprene) via the topical route by the animal owner. On 25-Jul-2022, the cat was found deceased, still wearing the collar. No other signs preceding death were reported. A necropsy was not performed. No further information was received.
Mort
Assessment: This product contains tetrachlorvinphos, an organophosphate insecticide, that is considered to have a good margin of safety in cats. The active ingredient is poorly absorbed across intact skin. If product residue were ingested only mild GI upset would be expected. Sudden death is not expected and other causes including unknown trauma or injury, toxin exposure, and underlying disease should also be considered in this case. Without diagnostics, including necropsy, further classification of the relationship between product use and outcome cannot be made. The information contained in this report is based on self-reported statements provided to the registrant during telephone interview(s). These self-reported descriptions of an incident have not been independently verified to be factually correct or complete descriptions of the incident. For that reason, information contained in this report does not and cannot form the basis for a determination of whether the reported clinical effects are causally related to exposure to the product identified in the telephone interviews.